Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest torsades de pointes Stories

2012-09-20 06:31:46

ALISO VIEJO, Calif., Sept. 20, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced several business updates. The highlights are being provided in connection with the company's presentation today at the UBS Global Life Sciences Conference in New York City. Highlights include: Exceeding 10,000 total NUEDEXTA® prescriptions for the month of August. NUEDEXTA prescriptions of 10,710 in August represent 9% growth over the month of July. August monthly...

2012-08-03 02:24:14

ALISO VIEJO, Calif., Aug. 3, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) announced today that an additional patent covering Avanir's NUEDEXTA® (dextromethorphan HBr and quinidine sulfate) product has been listed in the U.S. Food and Drug Administration's (FDA) Orange Book. The Orange Book listing requires an Abbreviated New Drug Application (ANDA) applicant, seeking FDA approval for a generic version of NUEDEXTA prior to expiration of the patent, to notify Avanir...

2012-07-02 02:24:06

( ) ALISO VIEJO, Calif., July 2, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) announced today that the United States Patent and Trademark Office (USPTO) has allowed a new patent that covers Avanir's product NUEDEXTA®, further expanding the intellectual property portfolio for the company's lead commercial asset. This asset is a dual sigma-1 and NMDA receptor modulator that is approved for the treatment of pseudobulbar affect (PBA), and is in clinical development for...

2012-06-05 02:28:32

ALISO VIEJO, Calif., June 5, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced details of its Patient Assistance Program for NUEDEXTA® (dextromethorphan HBr and quinidine sulfate). The Patient Assistance Program is designed to help patients with a diagnosis of pseudobulbar affect which meet established program criteria gain access to NUEDEXTA free of charge. "NUEDEXTA is the first and only FDA approved medication indicated for pseudobulbar affect....

2011-11-17 07:30:00

ALISO VIEJO, Calif., Nov. 17, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) announced today that the European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for NUEDEXTA® (dextromethorphan HBr and quinidine sulfate) for the treatment of pseudobulbar affect (PBA). Acceptance of the MAA confirms that the submission is sufficiently complete to permit a substantive review. NUEDEXTA was approved by the U.S....

2011-10-18 07:30:00

ALISO VIEJO, Calif., Oct. 18, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from clinical research activities will be highlighted at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Amsterdam, the Netherlands. ECTRIMS is considered the world's largest annual international conference devoted to basic and clinical research in multiple sclerosis. Following are...

2011-08-11 07:30:00

ALISO VIEJO, Calif., Aug. 11, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that it has filed lawsuits in the U.S. District Court for the District of Delaware against Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc (collectively "Par") and Actavis South Atlantic LLC and Actavis, Inc. (collectively "Actavis"). The lawsuits were filed in response to Abbreviated New Drug Applications ("ANDAs") filed by Par and Actavis. In their...

2011-07-26 07:30:00

ALISO VIEJO, Calif., July 26, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced several positive developments regarding its anticipated European regulatory filing of NUEDEXTA® (dextromethorphan hydrobromide and quinidine sulfate) capsules for the treatment of pseudobulbar affect (PBA). On July 22, 2011, company officials met with the European Medicines Agency (EMA) to discuss plans for filing a marketing authorization application (MAA)...

2011-07-01 07:30:00

ALISO VIEJO, Calif., July 1, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) website indicates that an Abbreviated New Drug Application (ANDA) for a generic version of NUEDEXTA® (dextromethorphan hydrobromide and quinidine sulfate) capsules was submitted on March 7, 2011. The company received Paragraph IV certification notices on June 30, 2011. Avanir intends to vigorously enforce its...

2011-05-16 07:30:00

ALISO VIEJO, Calif., May 16, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from a number of clinical research activities will be highlighted at the 164th Annual Meeting of the American Psychiatric Association (APA) taking place in Honolulu, HI, at the Hawaii Convention Center. Following are details about the data presentations: Title: The Safety of Dextromethorphan/Quinidine in Clinical Trial Participants Taking Selective Serotonin Reuptake...